Immunic Presents New Phase 2 CALLIPER Data, Secures $400M for Vidofludimus Calcium
Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.